Physician profile
Sanjay Lamba
NPI 1619060449
$3,233.71
in general payments reported to CMS, 2019-2025
28 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $177 · 2021: $515 · 2022: $456 · 2023: $820 · 2024: $362 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,592.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $830.23 | 2019-2024 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $383.26 | 2021-2023 | Krystexxa |
| Amgen INC. | $285.41 | 2019-2025 | Krystexxa, Tavneos |
| Vifor Pharma, INC. | $223.89 | 2021 | |
| Aurinia Pharma U.S., INC. | $168.14 | 2023-2024 | Lupkynis |
| Opko Pharmaceuticals, LLC | $147.12 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.22 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $109.51 | 2023-2025 | |
| Nxstage Medical, INC. | $101.65 | 2023 | Nxstage System One, Liberty Select Cycler |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $96.69 | 2025 | |
| Mallinckrodt Hospital Products INC. | $82.34 | 2020-2024 | Acthar |
| Kyowa Kirin, INC. | $81.62 | 2023-2025 | Crysvita |
| Glaxosmithkline, LLC. | $77.94 | 2021-2024 | Jesduvroq, Benlysta |
| Otsuka America Pharmaceutical, INC. | $70.00 | 2019-2025 | Jynarque |
| Takeda Pharmaceuticals U.S.A., INC. | $56.21 | 2022-2023 | Livtencity |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $54.25 | 2022-2025 | Vafseo |
| Daiichi Sankyo INC. | $45.15 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $41.49 | 2023-2024 | Ultomiris |
| Amicus Therapeutics, INC. | $38.05 | 2020-2022 | |
| Fresenius USA Marketing, INC. | $37.13 | 2019-2024 | Velphoro |
| Outset Medical INC | $34.07 | 2023 | |
| Novo Nordisk INC | $27.95 | 2024 | Rivfloza |
| Ani Pharmaceuticals, INC. | $24.82 | 2022 | |
| Calliditas Therapeutics US INC. | $18.99 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.94 | 2023 | Givlaari |
| Travere Therapeutics, INC. | $16.44 | 2023 | |
| Strongbridge US INC. | $16.15 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Lamba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.